Anlotinib combined with neoadjuvant chemotherapy for HR+/HER2- breast cancer (ACNTBC): a prospective, single-arm, single-center phase II clinical study with real-world validation.

Signal Transduct Target Ther · 2026 · PMC13263349 · PMID 42285923

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

2 ) did not identify any clinical or pathological subgroup that consistently benefited substantially from anlotinib-based NAT in the tpCR or RCB 0/I rate, despite a numerical trend favoring node-negative (N0) patients.

also in 723 other papers

did not reach statistical significanceno p-value reported

Consequently, despite the numerical difference, the 2-year EFS rates did not reach statistical significance compared to the IPTW-weighted control group.

also in 75,281 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.